More than 20 clinical trials are investigating whether glucagon-like peptide-1 receptor agonists, such as Wegovy, Ozempic and Mounjaro, could act as therapies for Parkinson’s and Alzheimer’s diseases. Both conditions are characterized by brain inflammation.
The drugs mimic a gut hormone that suppresses appetite, and while weight loss and reductions in blood sugar can help calm inflammation, some of the medications spur anti-inflammatory results before weight loss happens. Because of this, researchers are seeing if there’s an undiscovered mechanism in GLP-1s.
A few studies have shown positive results in mice, and others have seen GLP-1s reducing liver inflammation in a pilot study among people, according to Nature. A current trial is now testing exenatide (Byetta, Bydureon) among patients with Parkinson’s, which is expected to conclude this year.
Apart from the drugs’ approved indications for Type 2 diabetes and chronic weight management, studies are researching how GLP-1s might affect cardiovascular diseases, addiction, dementia and cancer.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
